

Examiner Signature	T. A. Soltis	Date Considered	2-24-07
-----------------------	--------------	--------------------	---------



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	10/782,060
Filing Date	February 18, 2004
First Named Inventor	Bart DeCorte et al.
Group Art Unit	
Examiner Name	T. A. Solola
Attorney Docket Number	PRD-26CIP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
YD		5,753,659		Stuart Dennet Mills	05-19-1998	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ²
		Office ³	Number ⁴	Kind Code ⁵				
YD		WO	04/020435	A1	Janssen Pharmaceutica N.V., Belg.	03-11-2004		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
YD		HOEKSTRA, William J., "Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotnic Acid Subunit. Structure-Activity Studies Leading to the Discovery of RWJ-53308", Journal of Medicinal Chemistry, American Chemical Society, Washington, US, Vol. 42, No. 25, 1999, pp. 5254-5265	

Examiner Signature	T. A. Solola	Date Considered	2-24-07
-----------------------	--------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 4

Application Number	10/782/060
Filing Date	February 18, 2004
First Named Inventor	DeCorte, B.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-26 CIP

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code ² (if known)			
Yo		4,289,772		Campbell, S. et al.	09-15-1981	
		6,211,191	B1	Meissner, R.S. et al.	04-03-2001	
		5,919,792	B1	Duggan et al	07-06-1999	
		5,855,866		Thorpe et al	01-05-1999	
		6,342,219		Thorpe et al	01-29-2002	
		5,902,795		Toole et al	05-11-1999	
		5,762,918		Thorpe	06-09-1998	
		5,474,765		Thorpe	12-12-1995	
		2002/0016625	A1	Fabrizio et al	02-07-2002	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T ³
		Office ³	Number ⁴	Kind Code ⁵				
Yo		WO	9409029		Merck and Co., Inc.	04-28-1994		
		WO	99/31061	A1	Merck and Co., Inc.	06-24-1999		
		WO	00/72801	A2	Merck and Co., Inc.	12-07-2000		
		WO	01/96334	A2	Pharmacia Corporation	12-20-2001		
		WO	01/23376	A1	Ortho-McNeil Pharmaceutical, Inc.	04-05-2001		
		WO	00/35887	A2	Du Pont Pharmaceuticals Company	06-22-2000		
		WO	00/35492	A2	Du Pont Pharmaceuticals Company	06-22-2000		

Examiner Signature	T. A. Solala	Date Considered	2-24-07
-----------------------	--------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	10/782/060
--------------------	------------

10/782/060

<i>Filing Date</i>	February 18, 2004
--------------------	-------------------

February 18, 2004

First Named Inventor	DeCorte, B.
-----------------------------	-------------

DeCorte, B.

<i>Group Art Unit</i>	1646
-----------------------	------

1646

Examiner Name	Not yet assigned
----------------------	------------------

Not yet assigned

Attorney Docket Number	PRD-26 CIP
------------------------	------------

PRD-26 CIP

FOREIGN PATENT DOCUMENTS


[illegible]

Examiner Signature	T. A. Solala	Date Considered	2-24-67
-----------------------	--------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO:** Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/782/060
Filing Date	February 18, 2004
First Named Inventor	DeCorte, B.
Group Art Unit	1646
Examiner Name	Not yet assigned
Attorney Docket Number	PRD-26 CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
YD		KATANO, K. et al: "Tetrahydrothienopyridine derivatives as novel GPIIb/IIIa antagonists". Bioorganic & Medicinal Chemistry Letters (1996), 6(21), 2601-2606.	
		KLEIN, S.I. et al: "Design of a New Class of Orally Active Fibrinogen Receptor Antagonists". Journal of Medicinal Chemistry (1998), 41(14), 2492-2502.	
		GRUMEL, V. et al: "Synthesis of Substituted Oxazolo '4,5-bipyridine Derivatives". Heterocycles (2001), 55(7), 1329-1345.	
		FISHER, M.J. et al: "Fused Bicyclic Gly-Asp-beta-turn Mimics with Potent Affinity for GPIIb-IIIa. Exploration of the Arginine Isostere". Bioorganic & Medicinal Chemistry Letters (2000), 10(4), 385-389.	
		LAWSON, E.C. et al: "1,2,4-Triazolo '4,3-olpyridine as a Novel, Constrained Template for Fibrinogen Receptor (GPIIb/IIIa) Antagonists: Bioorganic & Medicinal Chemistry Letters (2001), 11(19), 2619-2622.	
		SU, T. et al: "Fibrinogen Receptor (GPIIb-IIIa) Antagonists Derived From 5,6-Bicyclic Templates. Amidinoindoles, Amidinoindazoles, and Amidinobenzofurans Containing the N-Alpha-Sulfonamide Carboxylic Acid Function as Potent Platelet Aggregation Inhibitors". Journal of Medicinal Chemistry, American Chemical Society, Washington, U.S., vol.40, no.26, 1997, pages 4308-4318.	
		VARON, D. et al: "Inhibition of Integrin-Mediated Platelet Aggregation, Fibrinogen-Binding, and Interactions with Extracellular Matrix by Nonpeptidic Mimetics of Arg-Gly-Asp". Thrombosis and Haemostasis, Stutthard, DE vol. 70, no.6, 1993, pages 1030-1036.	
		VALERIE, A. et al. "2,4-Diamino-6,7-dimethoxyquinazolines, 2-(4-Carbamoylpiperidino) Derivatives as alpha1-Adrenoceptor Antagonists and Antihypertensive Agents". Journal of Medicinal Chemistry, American Chemical Society, Washington, U.S. vol.30, 1987, pages 999-1003.	
		ISHIHARA, Y. et al. "Regioselective Friedel-Crafts Acylation of 2,3,4,5-Tetrahydro-1H-2-Be Nzapazine and Related Nitrogen Heterocycles". Journal of the Chemical Society, Perkin Transactions 1, Chemical Society, Letchworth, GB, vol. 20, 1994, pages 2993-2999.	
		SAMANEN, J. et al. "Vascular Indications for Integrin Alphav Antagonists". Current Pharmaceutical Design, Bentham Science Publishers, Schiphol, NL, vol. 3, 1997, pgs. 545-584.	
		Amon, et al., Monoclonal Antibodies for Immunotargeting of Drugs in Cancer Therapy, Monoclonal Antibodies and Cancer Therapy, Reisfeld, et al. (eds.), pp. 243-256 (Alan R. Liss, Inc. 1985)	
		Brooks et al., Cell, 1994, 79, 1157-1164	
		de Groot FM, et al, "Design, synthesis, and biological evaluation of a dual tumor-specific motive containing integrin-targeted plasmin-cleavable doxorubicin prodrug, Mol. Can Ther. Sept. 2002, (11) pp. 901-911	


Examiner Signature	T. A. Solola	Date Considered	2-24-07
--------------------	--------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 4 of 4	Application Number	10/782/060
	Filing Date	February 18, 2004
	First Named Inventor	DeCorte, B.
	Group Art Unit	1646
	Examiner Name	Not yet assigned
	Attorney Docket Number	PRD-26 CIP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
YD		G.G. Bishop, "Selective αvβ3-Receptor Blockade Reduces Macrophase Infiltration and Restenosis After Balloon angioplasty in the Atherosclerotic Rabbit", <i>Circulation</i> , April 10, 2001, pp.1906-1911	
		F.A.L.M. Eskens, "Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the Integrins αvβ3 and αvβ5 in patients with advanced solid tumors", <i>European Journal of Cancer</i> , 39, (2003), pp. 917-926	
		Hellstrom, et al., <i>Antibodies for Drug Delivery, Controlled Drug Delivery (2nd Ed.)</i> Robinson, et al. (eds), pp. 623-53 (Marcel Dekker, Inc. 1987)	
		Hood, J.D., et al, Tumor Regression by Targeted Gene Delivery to the Neovasculature, <i>Science</i> , 2002, 28 June, 296, 2404-2407	
		R.O. Hynes, "A reevaluation of integrins as regulators of angiogenesis", <i>Nature Medicine</i> , Vol. 8, No. 9, Sept. 2002, pp. 918-921.	
		W.J. Hoekstra, <i>Current Medicinal Chemistry</i> , 1998, 5, 195	
		<i>International J. Pharm.</i> , 1986, 33, 201-217	
		Xiao-Zhu Huang, et al., Inactivation of the Integrin 6 Subunit Gene Reveals a Role of Epithelial Integrins in Regulating Inflammation in the Lungs and Skin, <i>Journal of Cell Biology</i> , 1996, 133, 821-28	
		Melpo Christofidow-Solomindou, et al., Expression and Function of Endothelial Cell on Integrin Receptors in Wound-Induced Human Angiogenesis in Human Skin/SCID 25 Mice Chimeras, <i>American Journal of Pathology</i> , 1997, 151, 975-83	
		M.C. Friedlander, et al., <i>Science</i> , 1995, 270, 1500-1502	
		Kerr, J.S., "The alpha v integrin antagonists as novel anticancer agents: an update", <i>Expert Opin Investg Drugs</i> , 2002 Dec; 11(12):1765-74	
		R.M. Lafrenie, "Involvement of Integrin αvβ3- in the Pathogenesis of Human Immunodeficiency Virus Type 1 Infection in Monocytes", <i>Virology</i> 297, 2002, pp. 31-38	
		S.A. Mousa, Anti-Integrin as novel drug-discovery targets: potential therapeutic and diagnostic implications", <i>Curr Opin. Chem. Biol.</i> Aug. 2002; 6(4), pp.534-541	
		S.A. Mousa, et al., <i>Emerging Therapeutic Targets</i> , 2000, 4, (2), 143-153	
		S.A. Mousa, et al., <i>Exp. Opin. Thera.Patents</i> , 1999, 9 (8), 1237-1248	
		S.A. Mousa, et al., αv Vitronectin Receptors in Vascular-Mediated Disorders", <i>Medicinal Research Reviews</i> , Vol. 23, No. 2, 190-199	
		Mehta et al. (<i>Biochem J.</i> , 1998, 330, 861)	
		<i>J Pharm. Sci.</i> , 1977 (Jan), 66, 1, 1	
		S.B. Rodan and G.A. Rodan, Integrin Function in Osteoclasts, <i>Journal of Endocrinology</i> , 1997, 154:S47-S56	
		Ross, R., <i>Nature</i> , 1993, 362, 801-809	
		C.M. Storgard, et al, Decreased Angiogenesis and Arthritic Disease in Rabbits Treated with an αvβ Antagonist, <i>J. Clin. Invest.</i> , 1999, 103, 47-54	
		W. H. Miller, et al., <i>Drug Discovery Today</i> , 2000, 5(9), 397-407	
		Thorpe, Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review, <i>Monoclonal Antibodies '84: Biological and Clinical Applications</i> , Pinchera, et al. (eds.), pp. 475-506 (1985)	
		Yin, L. et al., "Correlation of cell apoptosis induction with expression of human beta 5 integrin on hematopoietic cells", <i>Zhonghua Xue Ye Xue Za Zhi</i> , Jan 2001, 22(1) pp. 13-16	
✓		H. Zhang et al., "p21-activated kinase 4 interacts with integrin αvβ5-mediated cell migration", <i>The Journal of Cell Biology</i> , vol. 158, No. 7, September 30, 2002, pp. 1287-1297	

Examiner Signature	T. A. Solberg	Date Considered	2-24-07
--------------------	---------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.